A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With MTX Versus Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 > 3,2)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Albacete, Spain, 02006
-
Badajoz, Spain, 06080
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08003
-
Barcelona, Spain, 08035
-
Barcelona, Spain, 08907
-
Barcelona, Spain, 08025
-
Caceres, Spain, 10310
-
Cordoba, Spain, 14004
-
Granada, Spain, 18014
-
Granada, Spain, 18003
-
Guadalajara, Spain, 19002
-
Leon, Spain, 24071
-
Lugo, Spain, 27004
-
Madrid, Spain, 28040
-
Madrid, Spain, 28046
-
Madrid, Spain, 28034
-
Madrid, Spain, 28905
-
Madrid, Spain, 28041
-
Madrid, Spain, 28007
-
Madrid, Spain, 28031
-
Malaga, Spain, 29009
-
Salamanca, Spain, 37007
-
Sevilla, Spain, 41013
-
Sevilla, Spain, 41009
-
Tenerife, Spain, 38010
-
Toledo, Spain, 45004
-
Valencia, Spain, 46017
-
Valencia, Spain, 46010
-
-
Alicante
-
Orihuela, Alicante, Spain, 03314
-
Torrevieja, Alicante, Spain, 03186
-
Villajoyosa, Alicante, Spain, 03570
-
-
Badajoz
-
Merida, Badajoz, Spain, 06800
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08915
-
Granollers, Barcelona, Spain, 08402
-
Terrassa, Barcelona, Spain, 08221
-
-
Cadiz
-
Cádiz, Cadiz, Spain, 11009
-
-
Cantabria
-
Torrelavega, Cantabria, Spain, 39300
-
-
Castellon
-
Villarreal, Castellon, Spain, 12540
-
-
Islas Baleares
-
Menorca, Islas Baleares, Spain, 07701
-
-
La Coruña
-
A Coruna, La Coruña, Spain, 15006
-
Santiago de Compostela, La Coruña, Spain, 15706
-
-
Las Palmas
-
Las Palmas De Gran Canaria, Las Palmas, Spain, 35020
-
-
Madrid
-
Alcala de Henares, Madrid, Spain, 28805
-
Fuenlabrada, Madrid, Spain, 28942
-
Valdemoro, Madrid, Spain, 28342
-
-
Murcia
-
Cartagena, Murcia, Spain, 30203
-
El Palmar, Murcia, Spain, 30120
-
-
Pontevedra
-
Vigo, Pontevedra, Spain, 36214
-
-
Valencia
-
Manises, Valencia, Spain, 46940
-
Valenica, Valencia, Spain, 46009
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spain, 48903
-
Bilbao, Vizcaya, Spain, 48013
-
Galdakao, Vizcaya, Spain, 48960
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Active moderate to severe rheumatoid arthritis (DAS28 >/= 3.2) at baseline
- Currently receiving methotrexate for at least 12 weeks, at a stable oral dose of at least 15 mg/week for at least 6 weeks prior to treatment (Day 1)
- Body weight < 150 kg
- Oral corticoids must have been at stable dose for at least 25 out of 28 days prior to baseline; maximum dose 10 mg/day
Exclusion Criteria:
- Pregnant or nursing women
- Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline
- Rheumatic autoimmune disease other than RA
- Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis
- Prior history of or current inflammatory joint disease other than RA
- Treatment with a biologic agent at any time prior to baseline
- Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline
- Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline
- Previous treatment with RoActemra/Actemra
- History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
- Known active current or history of recurrent infection
- History of or currently active primary or secondary immunodeficiency
- Active tuberculosis requiring treatment within the previous 3 years
- Positive for HIV infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: A
|
orally, Week 1 - 16
orally, Week 17-28
8 mg/kg iv every 4 weeks, 28 weeks
|
|
ACTIVE_COMPARATOR: B
|
orally, Week 1 - 16
orally, Week 17-28
8 mg/kg iv every 4 weeks, 28 weeks
methotrexate placebo orally, Week 17-28
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Disease Activity Score Based on 28-Joint Count (DAS28) From Week 16 to Week 28
Time Frame: Baseline, Week 16, and Week 28
|
The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA).
The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (erythrocyte sedimentation rate [ESR] in millimeters per hour [mm/hr]), and general health status (participant global assessment of disease activity using visual analog scale [VAS], range 1-100 mm).
DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count.
The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
|
Baseline, Week 16, and Week 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With DAS28 Score Less Than (<) 2.6 at Week 28
Time Frame: Week 28
|
The DAS28 is a combined index for measuring disease activity in RA.
The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm).
DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count.
The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening.
DAS28 <2.6 equals (=) remission.
|
Week 28
|
|
Percentage of Participants With Clinical Disease Activity Index (CDAI) <2.8 at Week 28
Time Frame: Week 28
|
CDAI is the sum of tender and swollen joint count based on 28 joints and the participant and physician global disease assessment (VAS 0-10 centimeters [cm]).
CDAI total score 0-76; higher scores = greater affect due to disease activity.
CDAI <2.8 = clinical remission.
|
Week 28
|
|
Percentage of Participants With Simplified Disease Activity Index (SDAI) <3.3 at Week 28
Time Frame: 28 weeks
|
SDAI is calculated by a simple numerical sum of tender and swollen joint count (based on a 28-joint assessment), participant and physician global assessment of disease activity (VAS 0-10 cm), and level of C-reactive protein in milligram per deciliter (mg/dL).
SDAI total score 0-86; higher scores = greater affect due to disease activity.
SDAI <3.3 = clinical remission.
|
28 weeks
|
|
Change in the Health Assessment Questionnaire Disability Index (HAQ-DI) From Week 16 to Week 28
Time Frame: Week 16 and Week 28
|
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week.
Each item scored on 4-point scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do.
Overall score was computed as the sum of domain scores and divided by the number of domains answered.
Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
|
Week 16 and Week 28
|
|
Change in the Quality of Life Questionnaire (Short Form-12 [SF-12]) From Week 16 to Week 28 in Mental Health
Time Frame: Week 16 and Week 28
|
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health.
A negative change from baseline indicated decline in health and higher scores indicated improvement in health.
|
Week 16 and Week 28
|
|
Change in the Quality of Life Questionnaire (SF-12) From Week 16 to Week 28 in Physical Health
Time Frame: Week 16 and Week 28
|
Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health.
A negative change from baseline indicated a worsening of quality of life.
|
Week 16 and Week 28
|
|
Change From Week 16 to Week 28 in Global Assessment of Disease Activity as Assessed With the Visual Analogue Scale (VAS) Performed by Participant
Time Frame: Week 16 and Week 28
|
Participants were asked to rate their global assessment of disease activity on a scale ranging from 0=very good to 100=very bad.
The scale was represented by a line with 0 at the left edge and 100 at the right edge.
The participant was asked to mark the line corresponding to the assessment of their disease activity.
The distance from the left edge was measured in mm.
|
Week 16 and Week 28
|
|
Change From Week 16 to Week 28 in Global Assessment of Disease Activity Assessed Using the VAS Performed by the Investigator
Time Frame: Week 16 and Week 28
|
Participants were asked to rate their global assessment of disease activity on a scale ranging from 0=very good to 100=very bad.
The scale was represented by a line with 0 at the left edge and 100 at the right edge.
The participant was asked to mark the line corresponding to the assessment of their disease activity.
The distance from the left edge was measured in mm.
|
Week 16 and Week 28
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
Other Study ID Numbers
- ML27828
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.